根据最近的SEC文件，专注于纤维化疾病和癌症治疗开发的制药公司Galectin Therapeutics Inc. (NASDAQ: GALT )于2025年1月23日结束了2024年度股东大会，市值为7657万美元。股东就几个关键事项进行了投票。

Latest data shows the largest indicative borrow rate increases among liquid option names include: Galectin Therapeutics (GALT ...

NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line ...

It has been shown that the ß-galactoside binding lectin galectin-3 can promote fibrosis through altering cellular responses to TGFß. 1 However, the precise mechanism of this is currently unknown.

Geneos Wealth Management Inc. raised its stake in Galectin Therapeutics Inc. (NASDAQ:GALT – Free Report) by 10.2% in the 4th ...

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based ...

Galectin Therapeutics Inc.’s Stock Price as of Market Close As of January 15, 2025, 4:00 PM, CST, Galectin Therapeutics Inc.’s stock price was $1.280. Galectin Therapeutics Inc. is up 11.3% from its ...

【导读】肿瘤相关巨噬细胞（TAMs）通常被认为是肿瘤发生和肿瘤发展的帮凶。然而，肿瘤细胞促使 TAMs 协助逃避免疫监视的确切机制仍有待进一步研究。

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin is a carbohydrate-based drug ...